Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
0.796
+0.001 (0.16%)
Nov 21, 2024, 4:00 PM EST - Market closed
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -54.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 11.36, with a low estimate of 3.00 and a high estimate of 17.5. The average target predicts an increase of 1,326.96% from the current stock price of 0.80.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $22 → $14 | Buy | Maintains | $22 → $14 | +1,658.57% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +2,098.22% | Nov 8, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +1,407.35% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +2,098.22% | Sep 6, 2024 |
| Barclays | Barclays | Buy Maintains $10 → $3 | Buy | Maintains | $10 → $3 | +276.84% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.57
from -1.75
EPS Next Year
-1.24
from -1.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.40 | -0.56 | -0.39 | ||
| Avg | -1.57 | -1.24 | -1.04 | ||
| Low | -1.67 | -1.68 | -1.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.